世界の非アルコール性脂肪性肝炎（NASH）治療薬および診断市場：パイプライン治療薬、診断技術、治療法、地域別 - 成長、動向、予測
Hepatitis Therapeutics Market - Growth, Trends, and Forecast (2020 - 2025)
|発行||Mordor Intelligence LLP||商品コード||649745|
|出版日||ページ情報||英文 120 Pages
|世界の非アルコール性脂肪性肝炎（NASH）治療薬および診断市場：パイプライン治療薬、診断技術、治療法、地域別 - 成長、動向、予測 Hepatitis Therapeutics Market - Growth, Trends, and Forecast (2020 - 2025)|
|出版日: 2020年02月01日||ページ情報: 英文 120 Pages||
The Hepatitis Therapeutics Market is expected to register a CAGR of 3.5% during the forecast period. Hepatitis is an inflammation, or swelling, of the liver. Hepatitis may occur due to drugs, alcohol use, or certain medical conditions. But in most of the cases, it is caused by a virus called viral hepatitis, and the most common forms are hepatitis A, B, and C. Hepatitis is a very common disease and can lead to serious scarring (cirrhosis) of the liver and liver failure, which can be fatal.
Some of the common symptoms of hepatitis are loss of appetite, nausea and vomiting, fatigue, fever, body aches, and stomach pain. Some people may experience light-colored bowel movements, dark urine, and yellowing of the skin or of the eyes (jaundice). Viral infections of the liver are classified as hepatitis A, B, C, D, and E. A different virus is responsible for each type of virally transmitted hepatitis. Hepatitis A is an acute, short-term disease, while hepatitis B, C, and D are mostly ongoing and chronic. Hepatitis E is usually acute but can be particularly dangerous in pregnant women. Hepatitis can be diagnosed through history and physical exam, liver function tests, blood tests, and ultrasound. Some of the complications of hepatitis B or C are chronic liver disease, cirrhosis, and liver cancer.
According to the World Health Organization (WHO), globally, 500 million people are estimated to be infected with hepatitis B or C. About 1.5 million people die in a year due to hepatitis infection, 1 in every 3 people get infected and most of the infected people do not know about it due to dormant symptoms. In addition, in European Hepatitis B and C affect millions of people. In addition, According to the European Centre for Disease Prevention and Control (ECDC), estimates an overall incidence of hepatitis B is 1.49 (Per 100,000), hepatitis c is 8.7 (Per 100,000) in the member states of the European Union (EU) and high prevalence in people who inject drugs.
An increase in the prevalence of viral hepatitis, promising pipeline of hepatitis drugs, and supportive government initiatives encouraging patients in the adoption of hepatitis drugs are the key driving factors in the hepatitis therapeutics market.
Hepatitis C Segment is Expected to Hold a Major Market Share in the Hepatitis Therapeutics Market
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
North America expected to hold a major market share in the hepatitis therapeutics market due to an increase in the incidence of hepatitis, mortality due to hepatitis and increased spending on drugs for the treatment of hepatitis in this region. According to the Center for Disease Control (CDC), estimates about 2.4 million people are living with hepatitis C in the United States and approximately 850,000 people in this region estimated to be living with hepatitis B. In addition, 67% of persons infected with hepatitis B virus do not know they have the virus. Furthermore, favorable reimbursement policies, high adoption rates of advance therapeutics and the presence of well-established healthcare infrastructure are also fueling the growth of the overall regional market to a large extent.
The Hepatitis Therapeutics Market is fragmented competitive and consists of several major players. However, in terms of market share, few of the major players are currently dominating the market. Some of the leading market players include Merck & Co., Inc, Gilead Sciences, Inc, AbbVie Inc, Bristol Myers Squibb Company, F. Hoffmann-La Roche, Ltd, LAURUS Labs, Zydus Cadila, Hetero Healthcare Limited, NATCO Pharma Limited and Cipla, Inc.